Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Congenital STAT3 mutation Mediates Primary Persistent Polymorphic Inflammatory Activation and T Cell Leukemogenesis

Hongxing Liu

Blood (2019) 134 (Supplement_1): 1054.

https://doi.org/10.1182/blood-2019-132138

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Martha Hernandez-Illas, Tong Lin, Andres Rey, Jack Jenkins, Reddy Chandula, Mi Rim Choi, MD

Blood (2019) 134 (Supplement_1): 3817.

https://doi.org/10.1182/blood-2019-123695

Published: 2019

Journal Articles

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

Jinsong JIA, MD PhD, Hao Jiang, Xiao Jun Huang

Blood (2019) 134 (Supplement_1): 5019.

https://doi.org/10.1182/blood-2019-131670

Published: 2019

Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 925.

https://doi.org/10.1182/blood-2019-124407

Published: 2019

Journal Articles

Successful Management of Pregnancy with Severe Von Willebrand Disease in a Jehovah's Witness with Recombinant Von Willebrand Factor

Sajida Kazi, MRCP, FRCPATH, Ann Kinga Malinowski, MD MSc, FRCSC, Clare Whitehead, Kevin H. M. Kuo, MDMSc, FRCPC, Lynda Harrington, Nancy Watts, Chen Wang, MD PhD FRCPC, Nadine Shehata, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2018-99-114949

Published: 2018

Journal Articles

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Seok Jin Kim, MD PhD, Yong Park, MD, Yeung-Chul Mun, Jin Seok Kim, MD PhD, Kihyun Kim, MD PhD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2018-99-115447

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy Stark, MAS, Farrukh T. Awan, MD MS, Kami J. Maddocks, MD, Jennifer A. Woyach, MD, Thomas Whitlow, BA, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, MBA

Blood (2017) 130 (Supplement 1): 431.

https://doi.org/10.1182/blood.V130.Suppl_1.431.431

Published: 2017

Journal Articles

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

David Dale, MD, Audrey Anna Bolyard, RN, BS, Emily Dick, BA, Merideth L. Kelley, MS, Vahagn Makaryan, MD, Ramsey Johnson, MSM, Lu Gan, MD PhD, Sudha Parasuraman, MD

Blood (2017) 130 (Supplement 1): 995.

https://doi.org/10.1182/blood.V130.Suppl_1.995.995

Published: 2017

Journal Articles

Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study

Raymond SM Wong, MRCP,FRCP, Russell K Brynes, Attilio Orazi, Zeba Aziz, MD MBBS, Anait L. Melikyan, MD PhD, Abdulgabar Salama, Ozlem Ocak Arikan, Joan Maier, Tahir Shamsi, Professor of Haematology (FRCPath)

Blood (2017) 130 (Supplement 1): 3628.

https://doi.org/10.1182/blood.V130.Suppl_1.3628.3628

Published: 2017

Journal Articles

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients

Robert J Charnigo, MS, Beesan Tan, PhD, Denis Rybin, PhD, Debra D Pittman, MS, Krupa M. Sivamurthy, MBBS, MD, David Beidler, PhD, Nicholas Clarke, PhD

Blood (2017) 130 (Supplement 1): 3558.

https://doi.org/10.1182/blood.V130.Suppl_1.3558.3558

Published: 2017

Journal Articles

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Peter Martin, MD, Kristie Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Kami J. Maddocks, MD, Jia Ruan, MD PhD, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Giorgio Inghirami, MD, Pamela Harris, MD, Selina Chen-Kiang, PhD, John P. Leonard, MD

Blood (2016) 128 (22): 150.

https://doi.org/10.1182/blood.V128.22.150.150

Published: 2016

Journal Articles

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Zhuoyan Li, MD, Samuel M Rubinstein, MD, Carey Clifton, ACNP, Leigh Ann Vaughan, ACNP, Melissa Logue, ACNP, Michael T. Byrne, DO, Adetola A. Kassim, MD MS, Brian G Engelhardt, MD, Wichai Chinratanalab, MD, Salyka Sengsayadeth, MD, Stephen J. Brandt, MD, Stacey A. Goodman, MD MS, John P. Greer, MD, Madan Jagasia, MD, Bipin N. Savani, MD

Blood (2016) 128 (22): 3438.

https://doi.org/10.1182/blood.V128.22.3438.3438

Published: 2016

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: 1-Year Interim Analysis of Phase 2 Clinical Trial

Jong Wook Lee, Jun Ho Jang, Sung-Eun Lee, Chul Won Jung, Silvia Park, Il-Hoan Oh

Blood (2016) 128 (22): 3910.

https://doi.org/10.1182/blood.V128.22.3910.3910

Published: 2016

Journal Articles

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results

Guido Finazzi, MD, Bruno Martino, MD, Antonio Pezzuto, Andrzej Hellmann, MD, Mary Frances McMullin, MD, Richard Noble, MD, Nikolas von Bubnoff, Prof., PhD, Nathalie Cambier, MD, Jean-Pierre Marolleau, MD PhD, Marco Ruggeri, MD, Alessandro M. Vannucchi, MD PhD, Ruben Mesa, MD FACP, Raoul Tibes, MD PhD, Paolo Bettica, MD PhD, Silvia DI Tollo, DHSC, BSc, Alessandro Rambaldi, MD

Blood (2016) 128 (22): 4261.

https://doi.org/10.1182/blood.V128.22.4261.4261

Published: 2016

Journal Articles

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Susi Snitzler, RN, Olga Levina, RN, Tong (Trina) Wang, RN, Lisa W Le, MSc, Harminder Paul, Ellen Nong Wei, Anthea Lau, Michelle Queau, James B Johnston, MD, Suzanne Trudel, MD, Deborah A Smith

Blood (2015) 126 (23): 1742.

https://doi.org/10.1182/blood.V126.23.1742.1742

Published: 2015

Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1744.

https://doi.org/10.1182/blood.V126.23.1744.1744

Published: 2015

Journal Articles

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

Catherine S. Diefenbach, MD, Fangxin Hong, PhD, Jonathon B. Cohen, MD, Michael J. Robertson, MD, Richard F. Ambinder, MD PhD, Timothy S. Fenske, MD, Ranjana H Advani, MD, Brad S Kahl, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 585.

https://doi.org/10.1182/blood.V126.23.585.585

Published: 2015

NARROW

Congenital STAT3 mutation Mediates Primary Persistent Polymorphic Inflammatory Activation and T Cell Leukemogenesis

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Successful Management of Pregnancy with Severe Von Willebrand Disease in a Jehovah's Witness with Recombinant Von Willebrand Factor

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Efficacy and Safety of Romiplostim in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: 1-Year Interim Analysis of Phase 2 Clinical Trial

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only